Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Final Results

27th Jun 2014 16:08

RNS Number : 8073K
Taihua Plc
27 June 2014
 



 

Taihua plc

("Taihua" or the "Company")

Financial Results for the year ended 31 December

Chairman's Statement

 

This was the first year we benefitted from the sale of the harvest from the second forsythia plantation. Increased sales improved profitability but there was some offset as a result of higher harvesting costs and also a one -off increase in inventory provisioning of RMB 1.9m.

 

FY2013

FY2012

Sales

RMB 52.3m

RMB 39.2m

Profit before Tax

RMB 3.3m

RMB 2.9m

 

Segmental Sales Analysis (in RMB)

 

2013

2012

2011

Forsythia

41.8m

27.2m

29.0m

TCMs

5.7m

6.5m

12.2m

APIs

4.8m

5.5m

19.5m

Total

52.3m

39.2m

60.7m

 

Forsythia

Tonnage sold in 2013 was 1,528 tonnes (2012: 940 tonnes). The average selling price in 2013 was RMB 27.4/kg (2012: RMB 29.8/kg) excluding sales tax As previously announced, whilst the selling price for processed forsythia has increased, the selling price for unprocessed forsythia (which is what Taihua sells) has remained relatively stable.

 

Having completed the maiden harvest of the second plantation, it is the Board's intention to manage these assets and to not seek further expansion of forsythia cultivation.

 

Total cost of supply, including harvesting, packaging, plantation maintenance etc was RMB 19.87 per kg harvested in 2012 (RMB 18.66 per kg harvested in 2012). The increase was primarily due to the fact that the harvest tonnage was smaller in our first plantation but certain costs were fixed such as the plantation lease.

 

Finished Product TCMs

Bian Tong Pian sales were RMB 3.6m (2011: RMB 4.4m).

 

Box sales were 243,900 in 2013 (2012: 237,900). The lower sales revenue was reflective of a reduction in selling price from RMB 18.7 per box in 2012 to RMB 14.8 per box in 2013.

 

Bian Tong Pian is distributed in Beijing metropolitan district and Guangzhou military hospitals. It is also approved for sale in six further provinces, following Jilin province's approval in 2013. In provinces where Taihua has approval to sell but, as yet, no distribution agreements, prospective distributors continue to take small quantities to test the market.

 

There is no further progress to announce regarding Geng Nian An Capsule (dealing with menopause) and Zao Ren An Shen Keli (dealing with insomnia), in the Company's existing TCM range.

 

APIs

The supply of Paclitaxel API is increasingly competitive and as a result the average selling price has fallen significantly from RMB 468.4 per kg to RMB 391 per kg. Sales were approximately 8,910g in 2013. The sale of Paclitaxel by-products, which the Company expects to commence in the second half of 2014 should render this part of the business profitable overall. It is noted that RMB 1.5m of inventory provisioning in 2012 was no longer required in respect of Paclitaxel and this was written back to profit in 2013. Taihua is now self-sufficient in terms of the Yew tree raw material from which Paclitaxel is extracted.

 

Homoharringtonine sales continued to fall due in part to the government's delay in recertifying Taihua's GMP. As a result RMB 3.44m of inventory has passed the date after which we are not permitted to sell it in the Chinese market. As such Taihua has taken a 100% write-off against this inventory. The directors currently have no information regarding when this reaccreditation process will commence 910g of Homoharringtonine was sold in 2013.

 

Balance Sheet

Cash and cash equivalent fell from RMB 39.3m to RMB 34.5m. The main reason for the reduction in cash was the increasing forsythia sales. These are harvested and sold close to the year end and as such are largely in trade receivable at the end of 2013. 

 

The Board of Directors would like to place on record their appreciation of investors' interest in Taihua. Whilst the forsythia business has not been as profitable as was hoped at the outset, the transition from dependence on APIs is largely complete.

 

Annual General Meeting

The Company confirms that its Annual General Meeting will be held at 11am on 25 July at DWF LLP, 85 King William Street, London, EC4N 7BL and that the annual report and accounts will be dispatched to shareholders on30 June 2014 and will be available from the Company's website www.taihplc.com from that date.

 

Nicholas Lyth

Chairman

 

For further enquires please contact:

Nicholas Lyth, Taihua plc

+44776 990 6686

Katy Mitchell, WH Ireland Limited

+44 161 832 2174

 

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

Note

2013

2012

RMB'000

RMB'000

 

(restated)

 

Revenue

5

52,302

39,206

Cost of sales

(41,615

)

(27,114

)

Gross profit

10,687

12,092

Gain arising on revaluation of biological assets

12

1,077

(359

)

Other revenue

5

2,105

937

Selling expenses

(6,338

)

(5,246

)

General and administrative expenses

(4,229

)

(4,544

)

Profit before income tax

6

3,302

2,880

Income tax expense

7(a)

(1,212

)

(1,645

)

Profit for the year

2,090

1,235

Other comprehensive income/(loss) :-

Items that may be classified subsequently to profit or loss :-

Exchange differences arising on translation of

financial statements of foreign operations

 

98

 

(285

 

)

Other comprehensive income/(loss) for the year

98

(285

)

Total comprehensive income for the year

2,188

950

Profit attributable to :

Equity holders of the parent company

2,090

1,235

Total comprehensive income attributable to :

Equity holders of the parent company

2,188

950

Earnings per share :

8

Basic (RMB per share)

0.026

0.015

Diluted (RMB per share)

0.026

0.015

 

STATEMENTS OF FINANCIAL POSITION

AS AT 31 DECEMBER 2013

 

 

Note

 

At 31 December 2013

 

At 31 December 2012

 

At

1 January 2012

 

 

 

RMB'000

 

RMB'000

 

RMB'000

ASSETS

 

 

 

 

(restated)

 

(restated)

Non-current assets

 

 

 

 

 

 

 

Property, plant and equipment

9

 

2,046

 

2,241

 

2,133

Prepaid lease payments

10

 

53,450

 

56,400

 

24,700

Land use rights

11

 

1,408

 

1,446

 

1,484

Biological assets

12

 

4,563

 

4,076

 

5,002

Intangible assets

13

 

-

 

-

 

36

 

 

 

61,467

 

64,163

 

33,355

Current assets

 

 

 

 

 

 

 

Inventories

14

 

9,920

 

14,261

 

14,825

Trade receivables

15

 

58,039

 

40,507

 

49,081

Other receivables

16

 

714

 

364

 

430

Deposits and prepayments

17

 

2,791

 

3,665

 

4,323

Cash and cash equivalents

19

 

34,512

 

39,338

 

63,036

 

 

 

105,976

 

98,135

 

131,695

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

 

167,443

 

162,298

 

165,050

 

 

 

 

 

 

 

 

LIABILITIES

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Trade payables

20

 

2,236

 

571

 

315

Receipts in advance

 

 

182

 

498

 

229

Accrued expenses and other payables

21

 

14,722

 

12,634

 

17,741

Amounts due to related companies

18

 

1,148

 

1,148

 

40

Amount due to a shareholder

22

 

605

 

612

 

589

Amounts due to directors

23

 

6,721

 

6,808

 

6,094

Income tax payable

 

 

1,961

 

1,615

 

2,490

 

 

 

27,575

 

23,886

 

27,498

 

 

 

 

 

 

 

 

Net current assets

 

 

82,280

 

74,672

 

74,672

 

 

 

 

 

 

 

 

Non-current liability

 

 

 

 

 

 

 

Deferred tax liability

7(b)

 

221

 

953

 

1,043

 

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

 

27,796

 

24,839

 

28,541

 

 

 

 

 

 

 

 

NET ASSETS

 

 

139,647

 

137,459

 

136,509

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

 

 

 

Capital and reserves attributable to

 

 

 

 

 

 

 

Equity holders of the company

 

 

 

 

 

 

 

Share capital

24

 

12,357

 

12,357

 

12,357

Other reserves

25

 

19,148

 

19,050

 

19,335

Retained profits

 

 

108,142

 

106,052

 

104,817

 

 

 

 

 

 

 

 

TOTAL EQUITY

 

 

139,647

 

137,459

 

136,509

 

The financial statements were approved and authorised for issue by the Board of Directors on 27 June 2014.

 

 

................................. ..................................

DIRECTOR DIRECTOR

CONSOLIDATED STATEMENT OF CHANGES in EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 

Foreign

Merger

Reverse

General

Enterprise

currency

Share

Share

relief

Share

acquisition

reserve

expansion

translation

options

Retained

capital

reserve

premium

reserve

fund

fund

reserve

reserve

profits

Total

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

At 1 January 2012

12,357

64,364

4,783

(63,408

)

9,297

4,648

(843

)

494

111,646

143,338

Prior year adjustment (note 31)

(6,829

)

(6,829

)

At 1 January 2012, as restated

104,817

136,509

Profit for the year, as restated

-

-

-

-

-

-

-

-

1,235

1,235

Other comprehensive loss

-

-

-

-

-

-

(285

)

-

-

(285

)

Total comprehensive (loss)/income for the year, as restated

-

-

-

-

-

-

(285

)

-

1,235

950

At 31 December 2012 and 1 January 2013, as restaed

12,357

64,364

4,783

(63,408

)

9,297

4,648

(1,128

)

494

106,052

137,459

Profit for the year

-

-

-

-

-

-

-

-

2,090

2,090

Other comprehensive income

-

-

-

-

-

-

98

-

-

98

Total comprehensive income for the year

-

-

-

-

-

-

98

-

2,090

2,188

At 31 December 2013

12,357

64,364

4,783

(63,408

)

9,297

4,648

(1,030

)

494

108,142

139,647

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

2013

2012

RMB'000

RMB'000

(restated)

Cash flows from operating activities

Operating profit

3,302

2,880

Adjustments for :-

Increase/(reversal) in allowance for bad debts

1,051

(35

)

Amortisation of prepaid lease payments

2,950

1,300

Amortisation of land use rights

38

38

Amortisation of intangible assets

-

36

Depreciation

261

236

(Gain)/loss arising on revaluation of biological assets

(487

)

926

Change in fair value of harvested products

(590

)

(567

)

Interest income

(2,105

)

(647

)

increase in allowance for write-down of inventories

1,939

356

Written-off of prepayment

-

850

Operating cash flows before working capital changes

6,359

5,373

Decrease in inventories

2,992

775

(Increase)/decrease in trade receivables

(18,544

)

8,625

Increase in other receivables

(389

)

(129

)

Decrease/(increase) in deposits and prepayments

874

(192

)

Decrease in amount due from a director

-

179

Increase in trade payables

1,665

256

(Decrease)/increase in receipts in advance

(316

)

269

Increase/(decrease) in accrued expenses and other payables

2,088

(5,107

)

(Decrease)/increase in amounts due to related companies

-

1,108

(Decrease)/increase in amount due to a shareholder

(7

)

23

(Decrease)/increase in amounts due to directors

(87

)

714

Cash (used in)/generated from operations

(5,365

)

11,894

Interest received

2,105

647

Profits tax paid

(1,598

)

(2,610

)

Net cash (used in)/from operating activities

(4,858

)

9,931

Cash flows from investing activities

Purchase of property, plant and equipment

(66

)

(344

)

Lease premium payments

-

(33,000

)

Net cash used in investing activities

(66

)

(33,344

)

Net decrease in cash and cash equivalents

(4,924

)

(23,413

)

Cash and cash equivalents as at 1 January

39,338

63,036

Effect of foreign exchange change

98

(285

)

Cash and cash equivalents as at 31 December

34,512

39,338

Analysis of the balances of cash and cash equivalents

Cash and bank balances

34,512

39,338

 

 

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

 

1. GENERAL INFORMATION

 

Taihua Plc (the "Company") was incorporated and registered in England and Wales on 29 August 2006 under the Companies Act 1985 as a public company limited by shares with the name "China Natural plc" with registered number 05918155. On 8 September 2006, the Company changed its name to "Taihua plc". The address of the registered office is 4th Floor, Capital House, 85 King William Street, London, EC4N 7BL, and the principal place of business is Room 201, Unit 3, No. 16 Zhong Hua, ShiJiCheng, FuZeYuan, 239 KeJi Road, Hi-tech Zone, Xi An, 710077, People's Republic of China (the "PRC").

 

The Company is an investment holding company and its subsidiaries are principally engaged in the manufacturing and sales of pharmaceutical products. The consolidated financial statements are presented in Renminbi ("RMB"), the currency of the primary economic environment in which the trading company operates (note 3(r)).

 

 

2. Basis of preparation

 

(a) Compliance with International Financial Reporting Standards

 

The consolidated financial statements of the Company and its subsidiaries undertakings (the "Group") and the individual financial statements of the Company have been prepared in accordance with those International Financial Reporting Standards and Interpretations in force ("IFRSs"), as adopted by the European Union, and those parts of the Companies Act 2006 applicable to companies preparing financial statements under IFRSs.

 

The preparation of these financial statements in conformity with IFRSs also requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement and complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in Note 4 "Critical accounting estimates and judgements".

 

(b) Basis of consolidation

 

The consolidated financial statements include the financial statements of the Company and all of its subsidiaries undertakings as at 31 December 2013 using the acquisition method of accounting. The results of subsidiary undertakings acquired or disposed of during the year are included in the consolidated statement of profit or loss from the effective date of acquisition or up to the effective date of disposal, as appropriate.

 

All intra-group transactions, balances, income and expenses are eliminated on consolidation.

 

 

(b) Basis of consolidation (cont'd)

 

The acquisition of China Natural Pharmaceutical Limited ("CNP") by the Company on 26 September 2006 has been accounted for as a reverse acquisition in accordance with IFRS 3 "Business Combinations".

 

The Company became the legal parent of CNP by way of share exchange agreement. According to the share exchange agreement, the shareholders of CNP transferred the entire issued share capital of CNP to the Company in consideration for 73,390,800 ordinary shares of GBP 0.01 each. This business combination is regarded as a reverse acquisition whereby CNP, the legal subsidiary, is the acquirer and has the power to govern the financial and operating policies of the legal parent so as to obtain benefits from its activities.

 

(c) New IFRS standards and interpretations newly adopted

 

The Group has adopted the following new and amended IFRS standards and IFRIC interpretations:

 

· Amendments to IAS 12 "Deferred tax: Recovery of Underlying Assets"; and

· Amendments to IAS 1 "Presentation of items of Other Comprehensive Income"

 

The adoption of these revised standards has not had a material impact for the Group's result for the year and equity

 

(d) New IFRS standards and interpretations not yet adopted

 

The following standards, amendments and interpretations are not yet effective and have not yet been adopted early by the Group:

 

· Amendments to IFRS 7, IAS 1, IAS 19, IAS 27, IAS 32, IAS 36 and IAS 39;

· IFRS 9 Financial Instruments ;

· IFRS 10 Consolidated Financial Statements;

· IFRS 11 Joint Arrangement;

· IFRS 12 Disclosure of Interests in Other Entities;

· IFRS 13 Fair Value Measurement;

 

The management does not anticipate that the adoption of the above IFRS (including consequential amendments) and interpretations will result in any material impact to the financial statements in the period of initial application.

 

 

3. SIGNIFICANT ACCOUNTING POLICIES

 

The significant accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

 

(a) Subsidiaries

 

Subsidiaries are entities controlled by the Group. The Group controls an entity when it is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. When assessing whether the Group has power, only substantive rights (held by the Group and other parties) are considered.

 

Details of the subsidiaries of the Company at 31 December 2013 are as follows :-

 

Percentage of equity holding held by the Company

Proportion of voting

Name of

Place of

Registered

Directly

Indirectly

power held

Principal

subsidiary

establishment

capital

%

%

%

activities

China Natural Pharmaceutical Limited ("CNP")

BVI

US$1,000

100

-

100

Intermediate

holding

company

Taihua Natural Plant

Pharmaceutical Company Limited

("TNP")

PRC

HK$10,500,000

-

100

100

Production and sales of pharmaceutical

drugs

 

 

 

 

(b) Revenue recognition

 

Revenue from sales of goods is recognised when the significant risks and rewards of ownership of goods have been transferred to the buyerand measured at the fair value of the consideration received or receivable. Where a period of extended credit is given such that the time value of money is material the amounts receivable are discounted using prevailing market interest rates. The unwinding of this discount is recognised as interest on trade receivables and presented within other revenue.

 

Interest income is recognised on an effective interest basis.

 

(c) Segment reporting

 

Operating segments, and the amounts of each segment item reported in the financial statements, are identified from the financial information provided regularly to the Group's most senior executive management for the purposes of allocating resources to, and assessing the performance of, the Group's various lines of business and geographical locations.

 

Individually material operating segments are not aggregated for financial reporting purposes unless the segments have similar economic characteristics and are similar in respect of the nature of products and services, the nature of production processes, the type or class of customers, the methods used to distribute the products or provide the services, and the nature of the regulatory environment.

 

(d) Property, plant and equipment

 

Property, plant and equipment are stated at cost less accumulated depreciation and impairment losses.

 

Depreciation of property, plant and equipment is calculated on the straight-line basis to write off the cost of each asset to its estimated residual value over its estimated useful life. The estimated useful lives of property, plant and equipment are as follows :-

 

Buildings 20 - 40 years

Plant and machinery 5 - 8 years

Furniture, fixtures and equipment 5 - 10 years

Motor vehicles 5 years

 

 

 

 

(e) Land use rights

 

Land use rights represent operating lease payments paid to the PRC government authorities and a local cooperative for rights of 20 to 60 years.

 

Land use rights are stated at cost less accumulated amortisation and impairment losses. Land use rights are amortised using the straight-line basis over the unexpired period of the rights.

 

(f) Impairment of assets

 

Where an indication of impairment exists, or when annual impairment testing for an asset is required, recoverable amount is estimated. The recoverable amount is calculated as the higher of the asset's or cash-generating unit's value in use and its fair value less costs to sell, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case, recoverable amount is determined for the cash-generating unit to which the asset belongs.

 

An impairment loss is recognised if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to profit or loss in the period in which it arises.

 

(g) Biological assets

 

A biological asset is defined as a living plant controlled by an enterprise which is involved in the agricultural activity of the transformation of biological assets for sale, into agricultural produce, or into additional biological assets.

 

The fair values of Chinese Yew tree biological assets are based on the present value of expected net cashflows from the trees discounted at a current market-determined pre-tax rate (the "Valuation Methodology").

 

In the absence of an active open market, self-bred seedlings are stated at cost at the end of the reporting period and will be transferred to the category of infant trees upon transfer from the nursery to the plantation at their carrying value.

 

A gain or loss arising on initial recognition of biological assets at fair value less estimated harvesting and initial processing costs is recognised in profit or loss.

 

Agricultural produce harvested from the Group's biological assets is transferred to inventories at its deemed cost. The fair value of agricultural produce is based on market prices of Chinese Yew output from third party suppliers.

 

The biological assets growing on land that is occupied under an operating lease should be considered as biological assets where such living plants have a productive life that falls within the length of the operating leases. Accordingly shorter life plants cultivated on land utilised in accordance with an operating lease, are recognised as biological assets, and carried at fair value.

 

 

 

 

 

 

(h) Intangible assets

 

Intangible assets are stated in the consolidated statement of financial position at cost less accumulated amortisation and any impairment losses (see note 3(f)).

 

Amortisation of intangible assets is charged to profit or loss on a straight-line basis over the assets' estimated useful lives unless such lives are indefinite. Intangible assets represent non-patented technical know-how, which are amortised over their estimated useful lives.

 

(i) Inventories

 

Inventories are stated at the lower of cost and net realisable value. Cost is determined on the weighted average basis and, in the case of work in progress and finished goods, cost comprises direct materials, direct labour, and an appropriate proportion of overheads.

 

Net realisable value is based on estimated selling price less all further costs expected to be incurred to completion and disposal.

 

(j) Trade and other receivables

 

Trade receivables are measured at amortised cost using the effective interest method less allowances for impairments in respect of doubtful debts. An estimate for doubtful debts is made when there is objective evidence of impairment.

 

Other receivables, deposits and prepayments, and amounts due from related companies are recognised and carried at cost less allowance for any uncollectible amounts.

 

(k) Trade and other payables

 

Liabilities for trade and other payables which are normally settled on credit term of 180 days are carried at cost which is the fair value of the consideration to be paid in the future for goods and services received, whether or not billed to the Group.

 

Trade and other payables are not discounted as the time value of money in respect of these liabilities is not considered material.

 

(l) Provisions

 

A provision is recognised when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

 

When the effect of discounting is material, the amount recognised for a provision is the present value at the end of the reporting period of the future expenditure expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in profit or loss.

 

 

 

 

(m) Loans and borrowings

 

All loans and borrowings, which are interest-bearing, are initially recognised at cost, being the fair value of the consideration received net of issue costs associated with borrowing, and are subsequently measured at amortised cost using the effective interest rate method. Amortised cost is calculated by taking into account any issue costs, and any discount or premium on settlement.

 

Gains and losses are recognised in net profit or loss when liabilities are derecognised, as well as through the amortisation process.

 

(n) Borrowing costs

 

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets (that is, assets that necessarily take a substantial period of time to get ready for their intended use), are capitalised as part of the cost of those assets. Capitalisation of such borrowing costs ceases when the assets are substantially ready for their intended use.

 

Other borrowing costs are recognised as expenses in the period in which they are incurred.

 

(o) Operating leases

 

Leases where substantially all the rewards and risks of ownership of asset remain with the lessor are accounted for as operating leases. Rentals applicable to such operating leases are charged or credited to profit or loss on a straight-line basis over the lease terms.

 

(p) Research and development costs

 

Research and development costs are expensed as incurred.

 

An intangible asset would be recognised for certain development expenditure if applicable conditions were met, but to date all such expenditure has been expensed as incurred.

 

(q) Retirement benefits

 

Obligatory retirement benefits in the form of contribution under a defined contribution retirement schedule administered by local government agencies are charged to profit or loss as incurred.

 

 

 

(r) Foreign currency translation

 

The functional currency and the presentation currency of the Company are GBP and RMB respectively.

 

The functional currency of TNP is Renminbi ("RMB"), and the audited financial statements of TNP have been drawn up in RMB. As sales and purchases are denominated primarily in RMB and receipts from operations are usually retained in RMB, the Directors are of the opinion that RMB reflects the economic substance of the underlying events and circumstances relevant to the Group. Monetary assets and liabilities maintained in currencies other than RMB are translated into RMB at the approximate rates of exchange ruling at the end of the reporting period, differences on translation of monetary assets and liabilities are recognised in profit or loss.  Transactions in currencies other than RMB are translated at rates ruling on the transaction dates.

 

For the purposes of presenting the consolidated financial statements, the assets and liabilities of the Company and CNP, the Group's foreign operations, are translated into the presentation currency of the Group (i.e. RMB) at the rate of exchange prevailing at the end of the reporting period, and their income and expenses are translated at the average exchange rates for the year, unless exchange rates fluctuate significantly during the period, in which case, the exchange rates prevailing at the dates of transactions are used. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated as a separate component of equity (the foreign currency translation reserve). Such exchange differences are recognised in profit or loss in the period in which the foreign operation is disposed of.

 

The financial statements of the Company and CNP have been translated from GBP and HKD to RMB at the following exchange rates :-

 

Year-end rates Average rates

 

31 December 2013 £1 = RMB10.0827 £1 = RMB9.6978

HKD1 = RMB0.7885 HKD1 = RMB0.7991

 

(s) Income tax

 

Income tax comprises current and deferred tax. Current income tax is calculated based on the results for the year, adjusted for items which are not assessable or are disallowed.

 

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates that have been enacted or substantively enacted at the end of the reporting period.

 

 

(s) Income tax (cont'd)

 

Deferred tax liabilities are recognised for all taxable temporary differences. Deferred tax assets are recognised for all deductible temporary differences, carry-forward of unused tax assets and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, carry-forward of unused tax assets and unused tax losses can be utilised.

 

The Group does not recognise deferred tax liabilities, or deferred tax assets, on temporary differences associated with investments in subsidiaries where the parent company is able to control the timing of the reversal of the temporary differences and it is not considered probable that the temporary differences will revserse in the foreseeable future.

 

(t) Share-based payments

 

The cost of granting share options and other share-based remuneration to employees and Directors is recognised in profit or loss on a straight-line basis over the vesting period, based on the Group's estimate of shares that will eventually vest. These share-based payments are measured at fair value at the date of grant by use of the option pricing model known as the Black-Scholes formula using assumptions deemed to be consistent with the price which the incentive might have been worth if it was traded in the open market.

 

For equity-settled transactions with non-employees, the costs are recognised in profit or loss (or where they relate to issue costs, taken against the share premium account if appropriate) with measurement normally based on the fair value of goods or services received.

 

(u) Cash and cash equivalents

 

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks, and short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

 

 (v) Related parties

 

For the purposes of these consolidated financial statements, parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the party are subject to common control or common significant influence. Related parties may be individuals (being members of key management personnel, significant shareholders and/or their close family members) or other entities and include entities which are under the significant influence of related parties of the Group where those parties are individuals, and post-employment benefit plans which are for the benefit of employees of the Group or of any entity that is a related party of the Group.

 

4. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

 

In the process of applying the Group's accounting policies, management make various estimates and judgements (other than those involving estimates) based on past experience, expectations of the future and other information. The key sources of estimation uncertainty and the critical judgements that can significantly affect the amounts recognised in the financial statements are :-

 

Critical judgement

 

Forsythia plantation

Management has considered whether the prepaid lease arrangements described in note 10 should be classified as operating or finance leases. Although 20 years is an extended period of time, land has an indefinite useful life, and accordingly the lease term can reasonably be seen as less than the major part of the economic life of the underlying land. At the end of the lease all rights in the land revert to the lessor. Taking these factors into account, management has concluded that it does not enjoy substantially all the risks and rewards incidental to ownership of the land, and has concluded that these arrangements should be accounted for as operating leases.

 

Management has also considered whether biological assets that are growing on land that is occupied under an operating lease should also be recognised as biological assets in the group's accounts in accordance with the requirements of IAS 41. Management has concluded that where plants have a productive life that falls within the length of the operating leases, the assets can be properly said to be controlled by the company, and accordingly shorter life plants cultivated on land utilised in accordance with an operating lease, are recognised as biological assets, and carried at fair value.

 

However, where the group benefits from harvesting plants that have a useful life in excess of the length of the operating lease applying to the underlying land, management has concluded that it does not control the assets and accordingly does not recognise the land owner's biological assets in the group's balance sheet.

 

Consistent with these judgments, agricultural produce harvested from the landowner's biological assets is considered to be outside of the scope of IAS 41 and is recognised at cost. (Whereas agricultural produce from the group's recognised biological assets is recognised at the point of harvest at fair value less costs to sell, in accordance with IAS 41.)

 

Key Sources of Estimation Uncertainty

 

Fair Value of Biological Assets

Management estimates the current market prices less estimated harvesting and initial processing costs of biological assets at the end of the reporting period with reference to market prices. Management considers that there is presently an absence of effective financial instruments for hedging against the pricing risks with the underlying agricultural produce. Unexpected volatility in market prices of the underlying agricultural produce could significantly affect the fair values of these biological assets and result in fair value re-measurement changes in future accounting periods.

 

Further details on assumptions used and the sensitivity of the fair value of those assumptions are within note 12.

 

 

 

 

Key Sources of Estimation Uncertainty (cont'd)

 

Depreciation of property, plant and equipment

Property, plant and equipment are depreciated on a straight-line basis over their estimated useful lives, after taking into account their estimated residual values. The determination of the useful lives and residual values involves management's estimation. The Group assesses annually the residual values and the useful lives of the property, plant and equipment and if the expectation differs from the original estimate, such a difference may impact the depreciation in the year the estimate is changed and the future period.

 

Allowance for bad and doubtful debts

The Group makes provision for impairment of trade and other receivables based on an assessment of the recoverability of trade and other receivables. Provisions are applied to trade and other receivables where there is objective evidence that indicates the balances may not be collectible. The identification of doubtful debts requires the use of judgement and estimates based on the credit history of the customers or debtors and the current market conditions. Where the expectation is different from the original estimate, such difference will impact the carrying amount of receivables and impairment allowance in the period in which such estimate has been changed.

 

Allowance for inventories

The management of the Group reviews an ageing analysis at the end of each reporting period, and makes allowance for obsolete and slow-moving inventory items identified that are no longer suitable for use in production. The management estimates the net realisable value for such finished goods based primarily on the latest invoice prices and current market conditions. The Group carries out an inventory review on a product-by-product basis at the end of each reporting period and makes allowances for obsolete items.

 

Income tax expense

The Group is subject to income tax in the PRC. There are certain transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current income tax and deferred tax provisions in the period in which such determination is made.

 

 

5. REVENUE AND OTHER INCOME

 

Revenue on sale of goods represents the fair value of consideration received or receivable, net of value added tax ("VAT"), consumption tax ("CT") and other sales taxes and additional levi, after allowances for goods returns and trade discounts.

 

An analysis of the Group's revenue and other revenue is set out below :-

 

2013

2012

RMB'000

RMB'000

Revenue

 

Other revenue

52,302

39,206

Government subsidy

-

290

Interest on trade receivable

1,954

377

Interest income

151

270

Total revenue

54,407

40,143

 

 

 

6.

PROFIT BEFORE INCOME TAX

2013

2012

RMB'000

RMB'000

Profit before income tax is arrived at after charging/(crediting) :-

Auditors' remuneration

- Fees payable to the Company's auditor for the audit of the

Company's financial statements

205

215

Fees payable to the Company's auditor and its associates

for other services

- Other services charge pursuant to legislation

92

95

- Taxation services

13

13

Operating lease payments

220

239

Directors' remuneration

- Salaries

820

832

- Pension scheme costs

120

121

940

953

Other staff costs

- Salaries

1,641

1,877

- Pension scheme costs

663

653

2,304

2,530

Depreciation

261

236

Amortisation of prepaid lease payments

2,950

1,300

Amortisation of land use rights

38

38

Amortisation of intangible assets

-

36

Increase in allowance for write-down of inventories

1,939

356

Increase/(reversal) of allowance for bad debts

1,051

(35

)

 

In addition to the auditors' remuneration disclosed above, fees of RMB261,000 (2012: RMB261,000) were paid to PKF Hong Kong.

 

The average monthly number of employees (including Executive Directors) for the year for each of the Group's principal divisions was as follows :-

 

2013

2012

Sales representatives

33

33

Production and quality control

31

38

Administration department

18

22

Plantation area

1

1

83

94

 

7. Income tax expense

 

(a) Under tax law, a unified income tax rate is set at 25% for both domestic enterprises and foreign-invested enterprises.

 

Accordingly, TNP is subject to PRC enterprise income tax at the rate of 25% on its assessable profit for the years ended 31 December 2012 and 2013.

 

Income tax expense in the consolidated statement of profit or loss represents :-

 

2013

2012

RMB'000

RMB'000

(restated)

Current tax :-

Provision for the year

1,944

1,735

Deferred tax - Note 7(b)

Provision for the year

(732

)

(90

)

Income tax expense

1,212

1,645

 

The income tax expense of the Group's profit before income tax differs from the theoretical amount that would arise using the tax rate applicable to profit of the Group as follows :-

 

2013

2012

RMB'000

RMB'000

(restated)

Profit before income tax

3,302

2,880

Income tax based on the PRC statutory tax rate of 25%

825

720

Tax effect of non-taxable income

(389

)

-

Tax effect of non-deductible expense

373

495

Tax effect of unrecognised tax losses

403

430

Income tax expense

1,212

1,645

 

At the end of the reporting period, the Group has unused tax losses of RMB 12,921,000 (2012 : RMB 11,309,000) which represent the maximum benefit from unutilised tax losses of Taihua plc, which can be carried forward to offset against future taxable profits. The deferred tax assets of RMB 2,584,000 (2012 : RMB 2,261,000) relating to the tax losses have not been recognised as it is not certain whether the potential taxation benefit will be realised in the foreseeable future. All unutilised tax losses can be carried forward indefinitely.

 

 

 

(b) Deferred tax liability recognised by the Group and movements thereon during the current and prior yearare as follows :-

Fair value

Change in

gain of

fair value of

Other

biological

harvested

timing

assets

products

Differences

Total

RMB'000

RMB'000

RMB'000

RMB'000

At 1 January 2012 as restated

1,043

-

-

1,043

Credit to profit or loss for the year - Note 7(a)

(231

)

141

-

(90

)

At 31 December 2012 and 1 January 2013

812

141

-

953

Charge to profit or loss for the year - Note 7(a)

122

6

(860

)

(732

)

At 31 December 2013

934

147

(860

)

221

 

At the reporting date the aggregate amount of temporary differences associated with investments in subsidiaries for which deferred tax liabilities have not been recognised was RMB 7,013,000 (2012 : RMB 6,437,000). These differences arise on the profits retained by those subsidiaries that would be subject to withholding taxes if dividends were paid to their parent companies. Deferred tax has not been recognised in the statement of financial position as the Group is in a position to control the timing of the reversal of these temporary differences and it is probable that such differences will not reverse in the foreseeable future.

 

 

8. EARNINGS PER SHARE

 

Basic earnings per share

 

Basic earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year.

 

2013

2012

2012

(restated)

(as previously reported)

Profit attributable to equity holders of the

Company (RMB'000)

2,090

1,235

1,551

Weighted average number of ordinary shares

in issue (thousands)

81,737

81,737

81,737

Earnings per share (RMB per share)

0.026

0.015

0.019

 

 

 

 

 

 

 

 

 

 

Diluted earnings per share

 

The Company has only one category of dilutive potential shares - share options. A calculation is done to determine the number of shares that could have been acquired at fair value based on the monetary value of the subscription rights attached to outstanding share options. It is compared with the number of shares that would have been issued assuming the exercise of the share options.

2013

2012

2012

(restated)

(as previously reported)

Profit attributable to equity holders of the

Company (RMB'000)

2,090

1,235

1,551

Weighted average number of ordinary shares

in issue (thousands)

81,737

81,737

81,737

Adjustment for share options (thousands)

-

741

741

Weighted average number of ordinary shares

for diluted earnings (thousands)

81,737

82,478

82,478

Diluted earnings per share (RMB per share)

0.026

0.015

0.019

 

 

9. Property, plant and equipment

 

Furniture,

fixtures

Plant and

and

Motor

Buildings

machinery

equipment

vehicles

Total

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

Cost :-

At 1 January 2012

3,022

4,137

233

749

8,141

Additions

-

344

-

-

344

At 31 December 2012

3,022

4,481

233

749

8,485

Depreciation :-

At 1 January 2012

1,466

3,672

185

685

6,008

Provided

165

33

38

-

236

At 31 December 2012

1,631

3,705

223

685

6,244

Net book value :-

At 31 December 2012

1,391

776

10

64

2,241

At 31 December 2011

1,556

465

48

64

2,133

Cost :-

At 1 January 2013

3,022

4,481

233

749

8,485

Additions

-

66

-

-

66

At 31 December 2013

3,022

4,547

233

749

8,551

Depreciation :-

At 1 January 2013

1,631

3,705

223

685

6,244

Provided

165

86

10

-

261

At 31 December 2013

1,796

3,791

233

685

6,505

Net book value :-

At 31 December 2013

1,226

756

-

64

2,046

At 31 December 2012

1,391

776

10

64

2,241

 

10. PREPAID LEASE PAYMENTS

 

RMB'000

Cost :-

At 1 January 2012

26,000

Additions

33,000

At 31 December 2012, 1 January 2013 and 31 December 2013

59,000

Amortisation :-

At 1 January 2012

1,300

Provided

1,300

At 31 December 2012 and 1 January 2013

2,600

Provided

2,950

 

At 31 December 2013

5,550

Net book value :-

At 31 December 2013

53,450

At 31 December 2012

56,400

 

On 11 January 2011, TNP signed an agreement with Qin Bang Forsythia Cooperative in respect of leasing 893 hectares of Forsythia plantation for the period from 11 January 2011 to 11 January 2031, which are located in the Luonan region of Shanxi Province, the PRC.

 

Pursuant to the terms of the lease, TNP will manage the cultivation and benefit from the harvest from the plantation. The annual lease cost is RMB1,300,000 per annum, but it is a term of the lease that all 20 years were paid in advance. This payment has been capitalised and treated as a prepaid lease payment within non-current assets and will be amortised over the lease term of 20 years.

 

On 17 December 2012, TNP signed an agreement with Qin Yuan Forsythia Cooperative in respect of leasing 1,013 hectares of Forsythia plantation for the period from 1 January 2013 to 31 December 2032, which are located in the Luonan region of Shanxi Province, the PRC.

 

Pursuant to the terms of the lease, TNP will manage the cultivation and benefit from the harvest from the plantation. The annual lease cost is RMB1,650,000 per annum, but it is a term of the lease that all 20 years were paid in advance. This payment has been capitalised and treated as a prepaid lease payment within non-current assets and will be amortised over the lease term of 20 years.

11. LAND USE RIGHTS

 

The Group's interests in land use rights represent prepaid operating lease payments and their net book value is analysed as follows :-

 

RMB'000

Cost :-

At 1 January 2012, 31 December 2012 and 31 December 2013

1,911

Amortisation :-

At 1 January 2012

427

Provided

38

 

At 31 December 2012 and 1 January 2013

465

Provided

38

At 31 December 2013

503

Net book value :-

At 31 December 2013

1,408

At 31 December 2012

1,446

 

12. biological assets

 

Biological assets represent Chinese Yew trees (infant trees and seedlings) and Eucommia bush. The role of Chinese Yew trees is to provide the raw material for the extraction of Paclitaxel compound. For many years the Group has purchased this raw material from third party suppliers. In 2006, 2007 and 2008, it planted Chinese Yew trees in its own plantation.

 

Chinese Yew Trees

Eucommia bush

Total

RMB'000

RMB'000

RMB'000

At 1 January 2012

14,107

-

14,107

Prior year adjustment

(9,159)

54

(9,105

)

At 1 January 2012 as restated

4,948

54

5,002

Transfer of harvested produc as restated

(567

)

-

(567

)

Net change in fair value

(359

)

-

(359

)

At 31 December 2012 as restated

4,022

54

4,076

Transfer of harvested product

(590

)

-

(590

)

Net change in fair value

1,077

-

1,077

Valuation at 31 December 2013

4,509

54

4,563

 

Eucommia bush is the key raw materials to make one of the traditional Chinese medicine ("TCM") products. The Group does not harvest them as demand for TCM products are low. The quantity of these plants are a fraction of the whole plantation, the directors considered they are immaterial for fair value measurement, accordingly they are recognised at costs.

 

 

The number of infant Chinese Yew trees can be summarised in follows :-

 

2013

2012

Infant Trees

Mature Trees

Infant Trees

Mature Trees

Infant Trees planted in 2006

-

60,000

-

60,000

Infant Trees planted in 2007

-

50,000

-

50,000

Infant Trees planted in 2008

-

65,000

65,000

-

Infant Trees planted in 2009

-

-

-

-

Infant Trees planted in 2011

-

-

-

-

Infant Trees planted in 2012

-

-

-

-

Total Infant Trees planted

-

175,000

65,000

110,000

 

The initial harvest from infant Chinese Yew trees is 5 years after planting. The trees continue to mature and are estimated to have a harvestable life of 15 years. The harvest from any one Chinese Yew tree is 2kg per harvest. The trees can be harvested on a 3-4 year cycle.

 

In previous years it has not been possible to measure the fair value of infant trees reliably and they have therefore been valued at cost. However, as the trees approached maturity and the directors expected to commence harvesting during 2011, the trees were valued at their fair value less harvesting and initial processing costs in compliance with IAS 41 in the financial statements for the year ended 31 December 2010. However, as the permit to harvest in 2011 was not obtained from the relevant government body the first harvest now has take place in 2012. The effect of applying IAS 41 on the basis of valuation in the current year has been to increase the value of the biological assets by RMB1,077,000 (2012 : decreased by RMB 359,000).

 

The infant Chinese Yew trees are still undergoing biological transformation leading to them being able to produce material from which Paclitaxel compound can be extracted. Once these infant trees become mature and productive they are transferred into the mature trees category.

 

In arriving at the fair value less estimated harvesting and initial processing costs of the infant trees, the following major assumptions were made :-

 

(a) The market price variable represents the current price paid by the Group to its third party suppliers plus an allowance for inflation. No consideration has been given to any potential impact on the market price of the Chinese Yew resulting from the commencement of harvesting at the Group's own plantation.

 

(b) The harvest yield per tree is dependent on the age and health of the trees. This is affected in turn by climate, location and soil condition. Generally, harvesting can commence once the tree is 5 years old and will cease when it is 20 years old.

 

 

(c) The estimation of the costs of harvesting and initial processing have been determined by reference to actual costs incurred by the Group in the current year.

 

(d) A discount rate of 13% has been applied in determining the valuation.

 

(e) The harvest quantity is limited by reference to the local Government "Forestry Stocking Amounts" regulations. No consideration has been given to the potential impact of a change in these regulations.

 

(f) Other key assumptions include :-

 

(i) The demand for Chinese Yew will remain at current levels throughout the life of the plantation. The plantation does have a potential output approximately double the current demand.

 

(ii) Projected cashflows do not take into account taxation.

 

(iii) Cashflows are based on the current plantings and take no account of the impact of any additional or replacement plantings in the future.

 

The Group is exposed to number of risks in relation to its Chinese Yew plantation :-

 

(a) Regulatory and environmental risk

 

The Group is subject to laws and regulations in the jurisdiction in which it operates. The Group has established environmental policies and procedures aimed at compliance with local environmental and other laws. Management performs regular reviews to identify environmental risks and to ensure that the systems in place are adequate to manage those risks.

 

(b) Demand risk

 

The Group is exposed to risk from fluctuations in the demand for Paclitaxel and thus Chinese Yew. The Group undertakes regular reviews of its forecast of future demand for Paclitaxel and will modify its harvesting strategy as appropriate. The effect of a 10% decrease in market price of agricultural produces from the harvested trees on the fair value of the plantation would be RMB 697,000.

 

(c) Climate and other risks

 

The Group's plantation is exposed to the risk of damage from climatic changes, diseases, forest fires and other natural forces. The Group has extensive processes in place aimed at monitoring and mitigating those risks, including regular forest health inspections.

 

(d) Discount rate risk

 

The Board of Directors have assessed the model for assessing the fair value of the plantation and, bearing in mind the Group's capital costs and the risks associated with the project, the Board have decided that a discount rate of 13% is appropriate. Were circumstances to change that would warrant an increase in that rate by 1.0% to 14%, the fair value of the assets would fall by RMB 235,000.

 

 

 

 

13.

INTANGIBLE ASSETS

2013

2012

RMB'000

RMB'000

Cost :-

At beginning of the year and at end of the year

1,350

1,350

Accumulated amortisation :-

At beginning of the year

1,350

1,314

Charge for the year

-

36

At end of the year

1,350

1,350

Net book value :-

At end of the year

-

-

 

Intangible assets represent non-patented technical know-how obtained. They are amortised on a straight-line basis over their estimated useful lives. The amortisation charge for the year is included in cost of sales in the consolidated statement of profit or loss.

 

14.

Inventories

2013

2012

RMB'000

RMB'000

 

(restated)

 

Raw materials

4,371

1,902

Work in progress

7,493

9,915

Finished goods

1,860

4,310

13,724

16,127

Less : Write-down

(3,804

)

(1,866

)

9,920

14,261

 

The amount of inventory recognised as an expense during the year was RMB 39,464,000 (2012 : RMB 25,703,000).

 

The allowance for provision of inventories made in this year was RMB 1,939,000 (2012 : Nil).

 

At 31 December 2013, the value of inventories carried at net realisable value was RMB 3,352,000 (2012: RMB 973,000).

 

 

 

 

 

15.

Trade receivableS

2013

2012

RMB'000

RMB'000

 

Trade receivables

61,642

43,098

Less : Allowance for bad debts

(3,603

)

(2,591

)

58,039

40,507

 

The Group has granted general credit term of 180 days (2012: 180 days) to its customers.

 

The Directors consider that the carrying value of trade receivables approximates its fair value due to the short-term maturity.

 

Movements on the allowance for trade receivables are as follows :-

 

2013

2012

RMB'000

RMB'000

 

At 1 January

2,591

2,642

Increase/(reversal) in allowance for trade receivables

1,012

(51

)

At 31 December

3,603

2,591

 

As at 31 December 2013, trade receivables of approximately RMB8,088,000 (2012 : RMB10,889,000) were past due but not impaired.  These related to a number of independent customers for whom there is no recent history of default.  The ageing analysis of these receivables is as follows :-

 

2013

2012

RMB'000

RMB'000

Outstanding balances with ages :-

4 - 6 months

-

-

7 - 9 months

-

1,883

10 - 12 months

1,038

2,681

Within one year

1,038

4,564

Between one to two years

5,873

6,274

Between two to three years

1,129

-

Over three years

48

51

8,088

10,889

 

 

 

 

 

16.

other receivables

2013

2012

RMB'000

RMB'000

Other receivables

783

394

Less : Allowance for bad debts

(69

)

(30

)

714

364

 

The Directors consider that the carrying value of other receivables approximates its fair value due to the short-term maturity.

 

Movements on the allowance for other receivables are as follows :-

 

2013

2012

RMB'000

RMB'000

 

At 1 January

30

14

Increase in allowance for other receivables

39

16

At 31 December

69

30

 

As at 31 December 2013, other receivables of approximately RMB 714,000 (2012 : RMB364,000) were past due but not impaired.  These related to a number of independent parties for whom there is no recent history of default.  The ageing analysis of these receivables is as follows :-

 

2013

2012

RMB'000

RMB'000

Outstanding balances with ages :-

Within one year

443

126

Between one to two years

47

230

Between two to three years

217

5

Over 3 years

7

3

714

364

 

 

17.

deposits and prepayments

2013

2012

RMB'000

RMB'000

Deposits

103

1,989

Prepayments

2,688

1,676

2,791

3,665

 

 

 

 

18. AMOUNTS DUE to RELATED companIES

 

The amounts represents amounts due to the following related companies in which Liyi Chen, a Director of the Company, is also a shareholder and Director.

 

2013

2012

RMB'000

RMB'000

Sino Rise Offshore Limited

40

40

Xian Hai Sheng Technology Co. Ltd

1,108

1,108

1,148

1,148

 

The amounts are interest-free, unsecured and repayable on demand.

 

 

19. CASH AND CASH EQUIVALENTS

 

As at 31 December 2013, about 97.68% of the cash and bank balances of the Group were denominated in Renminbi, the remainder were held in GBP and HKD at the year end. Conversion of Renminbi balances into foreign currencies is subject to the rules and regulations on foreign exchange controls promulgated by the PRC government.

 

20.

tRADE PAYABLES

2013

2012

RMB'000

RMB'000

Trade payables

2,236

571

 

21.

accrued expenses and other payables

2013

2012

RMB'000

RMB'000

Salaries payable

176

167

Accruals

4,167

4,019

Pensions payable

5,800

5,015

Salaries tax payable

2,090

1,404

Sales tax payable

1,465

759

Other payables

1,024

1,270

14,722

12,634

 

22. AMOUNT DUE TO A SHAREHOLDER

 

The amount is interest-free, unsecured and repayable on demand.

 

 

23.

Amounts due TO directors

2013

2012

RMB'000

RMB'000

Chun Chai

26

26

Liyi Chen

6,695

6,782

6,721

6,808

 

The amounts are interest-free, unsecured and repayable on demand.

 

24.

SHARE Capital

2013

2012

Authorised :-

185,000,000 ordinary shares of GBP0.01 each

GBP 1,850,000

GBP1,850,000

Issued and fully paid :-

81,737,330 ordinary shares of GBP0.01 each

RMB 12,357,000

RMB12,357,000

 

Taihua plc has one class of ordinary shares which carry no right to fixed income.

 

Share options

 

On 31 August 2009, the Company granted 1,632,946 share options to the Non-Executive Directors. The exercise price of the options is GBP0.07 per ordinary share. The exercise period begins one year from the date of grant and ends on the tenth anniversary of the date of grant. The total estimated fair value of the options at the date of grant was RMB494,000. The options have been valued using the Black-Scholes model with the following main assumptions :-

 

Grant date

31 August 2009

Exercise price

GBP0.07

Expected life

5.5 years

Expected volatility

30.79%

Expected dividend yield p.a.

0%

Risk-free rate

2.71%

Expected forfeiture p.a.

0%

 

Volatility is the average annualised volatility of returns of the underlying stock's comparables.

 

No share-based payments were charged to profit or loss during both years.

25. OTHER RESERVES

 

The merger relief reserve represents the premium arising on the issue of equity shares by the Company to acquire TNP.

 

The share premium account represents the premium arising on the issue of equity shares by way of share placement, less expenses incurred.

 

The reverse acquisition reserve arose as a result of its reverse acquisition of the Company by TNP.

 

TNP, being a foreign investment enterprise, is required to appropriate an amount from the net profit reported in the statutory accounts to three statutory reserves, namely general reserve fund, enterprise expansion fund and staff welfare fund. All these funds are designated for specific purposes. Appropriations to the staff welfare fund are made at the discretion of the Directors. In accordance with the relevant laws and regulations of the PRC, it is required that not less than 10% of its net income (the percentage is upon approval from the Board of Directors' meeting), after offsetting any prior years' losses, for PRC reporting purpose is made to the general reserve fund. When the balance of such reserve reaches 50% of the registered capital, any further appropriation is optional. Upon approval from the Board of Directors of TNP, the statutory reserve can mainly be used to offset accumulated losses or to increase registered capital. Based on directors' resolutions, TNP appropriated 10% and 5% of its statutory net profit to the general reserve fund and the enterprise expansion fund for the period ended 31 December 2007. No such reserves were appropriated afterwards as they reached 50% of the registered capital.

 

The foreign currency translation reserve arose on translating financial statements of foreign operations into RMB.

 

The share option reserve arises on the recognition of expenses in respect of share-based payments to be settled with equity.

 

 

26. PENSION COSTS

 

The Group operates a statutory defined contribution pension plan for those employees who are eligible to participate in the plan. Contributions are made based on a percentage of the employees' relevant compensation and are charged to profit or loss in the year in which they become payable. The assets of the plan are held separately from those of the Group in an independently administered fund.

 

The pension costs charged to profit or loss represent contributions paid and payable by the Group to the plan and amounted to RMB783,000 and RMB774,000 respectively for the years ended 31 December 2013 and 2012.

 

 

27.

commitments

2013

2012

RMB'000

RMB'000

Capital commitments

Capital commitments in respect of the acquisition of intangible

assets and property, plant and equipment

Contracted but not provided for

300

300

Operating lease commitments

Future minimum lease payments under non-cancellable

operating leases for each of the following periods :-

Within one year

-

4

 

Operating lease payments represent rentals payable by the Group for its office premises and factories. The leases are negotiated for average terms of one to five years with fixed monthly rentals.

 

28. Related party transactions

 

Apart from the transactions as disclosed in Notes 18, 22 and 23 to the consolidated financial statements, the Group had no other material transactions with its related parties during the year.

 

Remuneration of Directors and key management personnel

2013

2012

RMB'000

RMB'000

Salaries, allowances and other benefits in kind

820

941

Pension scheme costs

120

135

940

1,076

 

 

 

 

The remuneration of Directors and key management personnel is analysed as follows :-

 

2013

Pensions

scheme

2012

Salaries

costs

Total

Total

RMB'000

RMB'000

RMB'000

RMB'000

Chong Cao*

194

-

194

200

Nicholas James Lyth*

194

-

194

200

Yunwu Liu*

108

30

138

138

Xin'an Zhou

-

-

-

123

Chun Chai*

108

30

138

139

Liyi Chen*

108

30

138

138

Zhaoyang Ma*

108

30

138

138

820

120

940

1,076

 

* Directors at 31 December 2013

 

29. FINANCIAL RISK MANAGEMENT, OBJECTIVES AND POLICIES

 

The Group's activities expose it to a variety of financial risks: foreign exchange risk, credit risk, liquidity risk and cash flow interest rate risk. The Group's overall risk management programme seeks to minimise potential adverse effects on the Group's financial performance.

 

(a) Categories of financial instruments

 

2013

2012

Financial

Financial

liabilities

liabilities

measured at

measured at

Loans and

amortised

Loans and

amortised

receivables

cost

receivables

cost

RMB'000

RMB'000

RMB'000

RMB'000

Trade receivables

58,039

-

40,507

-

Other receivables

714

-

364

-

Deposits

103

-

1,989

-

Cash and cash equivalents

34,512

-

39,338

-

Trade payables

-

2,236

-

571

Accrued expenses and other payables

-

11,167

-

10,471

Amounts due to related companies

-

1,148

-

1,148

Amount due to a shareholder

-

605

-

612

Amounts due to directors

-

6,721

-

6,808

93,368

21,877

82,198

19,610

 

 

 

 

 

 

 

 

 

(b) Financial risk factors

 

Foreign exchange risk

 

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

 

The Group mainly operates in the PRC with most of the transactions settled in RMB. It did not have significant exposure to foreign exchange risk.

 

During the year ended 31 December 2013, the Group had not entered into any forward exchange contracts.

 

Credit risk

 

Credit risk is the risk that a party to a financial instrument will cause a financial loss for the Group by failing to discharge an obligation.

 

The Group's credit risk is primarily attributable to trade receivables, other receivables and cash and cash equivalents. With respect to trade receivables, the Group has adopted credit policies, which include the analysis of the financial position of its clients and a regular review of their credit limits. The Group maintains an allowance for doubtful accounts and actual losses have been less than management's expectations and the Group has policies in place to ensure that sales are made to clients with an appropriate credit history. Also, the Group's cash and cash equivalents were held by major financial institutions located in the PRC, which management believes are of high credit quality. Accordingly, the overall credit risk is considered limited.

 

Carrying amounts of financial assets as at 31 December 2013, which represented the amounts of maximum exposure to credit risk, were as follows :-

 

2013

2012

RMB'000

RMB'000

Trade receivables

58,039

40,507

Other receivables

714

364

Deposits

103

1,989

Cash and cash equivalents

34,512

39,338

93,368

82,198

 

 

 

(b) Financial risk factors (cont'd)

 

Liquidity risk

 

Liquidity risk is the risk that the Group will encounter difficulty in meeting obligations associated with financial liabilities.

 

The Group monitors its liquidity risk and maintains a level of cash and cash equivalents deemed adequate by the management to finance the Group's operations and to mitigate the effects of fluctuations in its cash flows.

 

Maturities of the non-derivative financial liabilities of the Group as at 31 December 2013 were as follows :-

 

2013

2012

RMB'000

RMB'000

Total amounts of contractual undiscounted obligations :-

Trade payables

2,236

571

Accrued expenses and other payables

11,167

10,471

Amouunt due to related companies

1,148

1,148

Amount due to a shareholder

605

612

Amounts due to directors

6,721

6,808

21,877

19,610

Due for payment :-

Within one year or on demand

21,877

19,610

 

Interest rate risk

 

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

 

The Group's income and operating cash flows are substantially independent of the changes in market interest rates and the Group has no significant interest-bearing assets. The Group's exposure to changes in interest rates is mainly attributable to its short-term borrowings. The Group has not used any interest rate swaps to hedge its exposure to interest rate risk.

 

 

(c) Capital management

 

The primary objective of the Group's capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and to secure shareholders' investments.

 

The Group manages its capital structure and makes adjustments if required. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders by the means of share buy-backs or issue new shares. No changes were made in the objectives, policies or processes during 2013 and 2012.

 

As the Group operates in a high growth, fast moving industry, it is the Group's policy to maintain a high degree of flexibility in its capital structure by maintaining a high availability of liquid funds. The Group monitors its capital base using the equity ratio, which is total equity attributable to the Company's equity holders divided by total assets. The Group's current policy is to maintain an equity ratio of 50% or higher.

 

2013

2012

RMB'000

RMB'000

(restated)

Total assets

167,443

162,298

Total equity attributable to the Company's equity holders

139,647

137,459

Equity ratio

83.4%

84.7%

 

(d) Fair value estimation

 

(i) Financial instruments carried at fair value

At 31 December 2013, the Group did not have any financial instruments carried at fair value.

 

(ii) Fair value of financial instruments carried at other than fair value

 

The carrying amounts of the Group's financial instruments carried at cost or amortised cost were not materially different from their fair values as at 31 December 2013 and 2012.

 

 

30. SEGMENT REPORTING

 

For the purposes of resources allocation and performance assessment, the chief operating decision maker, Executive Director, regularly reviews revenue and cost of sales for each product.  The financial information provided to Executive Director, contain profit or loss information of each product line.  Therefore, the operation of the Group constitutes four reportable segments.

 

The Group's reportable segments under IFRS 8 Operating Segments are as follows :

 

· Paclitaxel - Paclitaxel is extracted from the bark of the yew tree (Taxus). This drug is one of the main-stream treatments for cancer of the ovaries, breast, certain types of lung cancer, and a cancer of the skin and mucous membranes more commonly found in patients with acquired immunodeficiency syndrome (AIDS).

 

· Homoharringtonine - Homoharringtonine is an alkaloid extracted from the branches and leaves of the Cephalotaxus tree. This drug has been prescribed for acute myeloid leukaemia and other cancers in China.

 

· TCM products - Traditional Chinese Medicine has recognition as a viable alternative health treatment and has been recognised by the World Health Organisation for its effectiveness in the treatment of certain forms of illnesses and diseases. The Company currently manufactures eight TCM products including Gengnianan Tablet, Duzhong Pingya Tablet, Zaoren Anshen Keli, Bunao Anshen Tablet, Jiangzi Jianfei Tablet, Dabaidu Capsule, Runing Tablet and Bian Tong Pian.

 

· Forsythia - Known as lian qiao in PRC, is a flowering shrub. The seeds and seed cases of this are harvested and, when dried, form the basis of TCM preparations. Forsythia TCMs are primarily sold to alleviate flu and cold like symptoms.

 

The Group's revenues are not significantly impacted by seasonality, except sales of forsythia. Forsythia is mainly harvested during autumn every year and therefore sales of forsythia are recognised in the fourth quarter.

 

 

 

Segment revenues and costs of sales

 

The following is an analysis of the Group's revenue and cost of sales by reportable segments :-

 

Homo-

TCM

Paclitaxel

harringtonine

Forsythia

products

Consolidated

Year ended 31 December 2013

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

Revenue

3,483

1,314

41,838

5,667

52,302

Cost of sales

(3,706

)

(4,092

)

(30,373

)

(3,444

)

(41,615

)

Gross profit

(223

)

(2,778

)

11,465

2,223

10,687

 

Homo-

TCM

Paclitaxel

harringtonine

Forsythia

products

Consolidated

Year ended 31 December 2012

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

Revenue

3,779

1,706

27,229

6,492

39,206

Cost of sales

(4,251

)

(820

)

(17,609

)

(4,434

)

(27,114

)

Gross (loss)/profit

(472

)

886

9,620

2,058

12,092

 

 

The management of the Company take into account revenue and costs of sales as the key performance indicators when they make management decisions.  Other costs are not allocated to operating segments as these are considered to be central operating costs of the business.  Assets and liabilities are not considered to be specific to individual operating segments and therefore separate analysis is not undertaken.

 

Entity-wide disclosures

 

All non-current assets and sales are located and generated in the PRC.

 

Total amounts of RMB42,117,000 (2012 : RMB27,229,000), which were individually more than 10 percent of the Group's revenue were revenue from transactions with four (2012 : four) single customers, details as follows :-

 

2013

2012

Forsythia segment

RMB'000

RMB'000

Customer A

11,484

7,655

Customer B

11,174

6,592

Customer C

9,139

7,399

Customer D

10,320

5,583

42,117

27,229

 

 

 

31. PRIOR PERIOD ADJUSTMENT

 

During the year the Group has revisited its policies and methodologies for valuing and accounting for its biological assets. As results, the directors have concluded that in accordance with the requirement of IAS 8 - Accounting policies, Changes in Accounting Estimates and Errors, prior year adjustments are required to restate the figures previously reported.

 

Former policy and methodology

The biological assets comprise of Yew trees cultivated on the land owned by the group (note 11). In previous years, an overall valuation was determined based upon the future economic benefits of the agricultural produce harvested from the Yew trees (that including the two By-Products extracted from the processed of agricultural produces). The initial measurement of the biological assets was charged or credited to the income statement at its first year of recogition. Subsequent period, the movement in valuation of the biological assets was charged to the Statement of Comprehensive Income and the inventory in the Statement of Financial Position.

 

Revised policy and methodology

For the current year, the overall valuation was determined based upon the future economic benefits of the agricultural produce harvested from the Yew trees only. This will exclude the future economic benefits of the two by-products, which does not fall within the scope of agricultural produce in accordance to IAS 41.

 

These changes have been applied retrospectively by restating the balance as at 1 January 2012 and 31 December 2012 with consequential adjustments to comparative for the year ended 31 December 2012 as follow:

 

As previously reported

Effect of change in policy

As restated

RMB'000

RMB'000

RMB'000

Consolidated statement of comprehensive income for the year ended 31 December 2012

Gain/(loss) arising on revaluation of biologica assets

64

(423

)

(359

)

Taxation

(1,752

)

107

1,645

Profit for the year

1,551

(316

)

1,235

Consolidated statement of financial position as at

31 December 2012

Biological assets

13,181

(9,105

)

4,076

Inventory

14,684

(423

)

14,261

Deferred tax liability

(3,336

)

2,383

(953

)

Net assets

144,604

(7,145

)

137,459

Retained profit

113,197

(7,145

)

106,052

Consolidated statement of financial position as at

1 January 2011

Biological assets

14,107

(9,105

)

5,002

Deferred tax liability

(3,319

)

2,276

(1,043

)

Net assets

143,338

(6,829

)

136,509

Retained profit

111,646

(6,829

)

104,817

 

 

 

 

COMPANY STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

2013

2012

Note

RMB'000

RMB'000

 

Auditors' remuneration

(469

)

(513

)

 

Directors' remuneration

(388

)

(404

)

 

Legal and professional fees

(306

)

(340

)

 

Sundry expenses

(449

)

(467

)

 

Loss before income tax

(1,612

)

(1,724

)

 

Income tax expense

2

-

-

 

Loss for the year

(1,612

)

(1,724

)

 

Other comprehensive income/(loss) :-

 

Exchange differences arising on translation

of financial statements

42

(288

)

 

Other comprehensive income/(loss) for the year, net of tax

42

(288

)

 

Total comprehensive loss for the year

(1,570

)

(2,012

)

 

Loss attributable to :

 

Equity holders of the parent company

(1,612

)

(1,724

)

 

Total comprehensive loss attributable to :

 

Equity holders of the parent company

(1,570

)

(2,012

)

 

 

 

COMPANY STATEMENT OF FINANCIAL POSITION

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

Note

2013

2012

RMB'000

RMB'000

ASSETS

 

NON-CURRENT ASSET

 

Investment in subsidiaries

3

75,437

75,437

 

CURRENT ASSETS

 

Other receivable

-

77

Cash and cash equivalents

38

261

 

 

38

338

 

TOTAL ASSETS

75,475

75,775

 

CURRENT LIABILITIES

 

Accrued expenses and other payables

536

543

Amount due to a subsidiary

4

2,172

803

Amount due to a shareholder

5

605

612

Amount due to a director

6

6,634

6,719

 

 

9,947

8,677

 

NET CURRENT LIABILITIES

(9,909

)

(8,339

)

 

NET ASSETS

65,528

67,098

 

EQUITY

 

Share capital

7

12,357

12,357

Merger relief reserve

64,364

64,364

Share premium

4,783

4,783

Share options reserve

494

494

Foreign currency translation reserve

(308

)

(350

)

Accumulated losses

(16,162

)

(14,550

)

 

EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF

THE COMPANY

65,528

67,098

 

 

The financial statements were approved and authorised for issue by the Board of Directors on 27 June 2014.

 

 

 

 

................................. ..................................

DIRECTOR DIRECTOR

 

 

COMPANY STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

Share

capital

Merger

relief

reserve

Share

premium

Share

options

reserve

Foreign

currency

translation

reserve

Accumulated

losses

Total

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

RMB'000

At 1 January 2012

12,357

64,364

4,783

494

(62

)

(12,826

)

69,110

Loss for the year

-

-

-

-

-

(1,724

)

(1,724

)

Other comprehensive loss

-

-

-

-

(288

)

-

(288

)

Total comprehensive loss for the year

-

 

-

-

-

(288

)

(1,724

)

(2,012

)

At 31 December 2012 and

1 January 2013

12,357

64,364

4,783

494

(350

)

(14,550

)

67,098

Loss for the year

-

-

-

-

-

(1,612

)

(1,612

)

Other comprehensive income

-

-

-

-

42

-

42

Total comprehensive income/(loss) for the year

-

-

-

-

42

(1,612

)

(1,570

)

At 31 December 2013

12,357

64,364

4,783

494

(308

)

(16,162

)

65,528

 

The merger relief reserve represents the premium arising on issue of equity shares by the Company to acquire TNP.

 

The share premium account represents the premium arising on the issue of equity shares by way of share placement, less expenses incurred.

 

The share option reserve arises on the recognition of expenses in respect of share-based payments to be settled with equity.

 

The foreign currency translation reserve arose on translating financial statements from functional currency into RMB.

COMPANY STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

2013

2012

RMB'000

RMB'000

Cash flows from operating activities

 

Loss before income tax and operating loss before working

capital changes

(1,612

)

(1,724

)

Decrease in amount due from a subsidiary

-

280

Decrease/(increase) in other receivable

77

(77

)

(Decrease)/increase in accrued expenses and other payables

(7

)

1

Increase in amount due to a subsidiary

1,369

803

(Decrease)/increase in amount due to a shareholder

(7

)

23

(Decrease)/increase in amount due to a director

(85

)

1,241

 

Net cash (used in)/generated from operating activities

And net (decrease)/increase in cash and cash equivalents

(265

)

547

 

Cash and cash equivalents as at 1 January

261

2

 

Effect of foreign exchange change

42

(288

)

 

Cash and cash equivalents as at 31 December

38

261

 

 

 

 

 

 

NOTES TO THE COMPANY FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2013

 

 

1. SIGNIFICANT ACCOUNTING POLICIES

 

The separate financial statements have been prepared in accordance with International Financial Reporting Standards as adopted by the European Union and with those parts of the Companies Act 2006 that is applicable to companies reporting under IFRS. The principal accounting policies adopted are the same as those set out in Note 3 to the consolidated financial statements except as noted below.

 

(a) Investment in subsidiaries

 

Investment in subsidiaries is stated at cost less, where appropriate, provisions for impairment.

 

(b) Foreign currency

 

The functional currency of the Company is Sterling. Monetary assets and liabilities maintained in currencies other than Sterling are translated into Sterling at the approximate rates of exchange ruling at the end of the reporting period, with any exchange difference recognised in profit or loss. Transactions in currencies other than Sterling are translated at rates ruling on the transaction dates.

 

The financial statements of the Company are presented in RMB, chosen because the revenue and expenses of the Group's main operation are ultimately denominated in RMB. Transactions in Sterling are translated to RMB at the average exchange rates for the year unless exchange rates fluctuate significantly. Sterling denominated assets and liabilities are converted to RMB at the exchange rate prevailing at the end of the reporting period. Exchange differences arising are transferred to foreign currency translation reserve.

 

2. Income tax expense

 

(a) No provision for income tax has been made in these financial statements as the Company has no assessable profit for the years ended 31 December 2013 and 2012.

 

The income tax expense of the Company's loss before income tax differs from the theoretical amount that would arise using the tax rate applicable to loss of the Company as follows :-

 

2013

2012

RMB'000

RMB'000

Loss before income tax

(1,612

)

(1,724

)

Income tax based on the UK statutory tax rate of 20%

(2012: 20%)

 

(322

 

)

 

(345

 

)

Tax effect of unrecognised tax losses

322

345

Income tax expense

-

-

 

(b) At the end of the reporting period, the Company has unused tax losses of RMB12,921,000 (2012 : RMB11,309,000) which represent the maximum benefit from unutilised tax losses, which can be carried forward to offset against future taxable profits. The deferred tax assets of RMB2,584,000 (2012 : RMB2,261,000) relating to the tax losses have not been recognised as it is not certain whether the potential taxation benefit will be realised in the foreseeable future. All unutilised tax losses can be carried forward indefinitely.

 

3.

INVESTMENT IN SUBSIDIARIES

2013

2012

RMB'000

RMB'000

Investment at cost

75,437

75,437

 

On 26 September 2006, the Company issued 73,390,800 ordinary share of GBP0.01 each in exchange for the entire share capital of China Natural Pharmaceutical Limited (BVI). The cost of acquisition was the fair value of the subsidiary, estimated by the Directors as being RMB75,437,000, equivalent of GBP5,000,000.

 

Details of the subsidiaries at 31 December 2013 are as follows :-

 

Proportion of ownership

Place and date of

Principal

and voting rights

Name of subsidiary

incorporation

activities

Direct

Indirect

China Natural Pharmaceutical

Limited

British Virgin Islands;

13 June 2006

Investment holding

100%

-

Taihua Natural Plant

Pharmaceutical Company

Limited

The People's Republic

of China;

22 February 1993

Production and

sales of

pharmaceutical

drugs

-

100%

 

4. AMOUNT DUE TO A SUBSIDIARY

 

The amount is interest-free, unsecured and repayable on demand.

 

5. AMOUNT DUE TO A SHAREHOLDER

The amount is interest-free, unsecured and repayable on demand.

 

6.

AMOUNT DUE TO A DIRECTOR

2013

2012

RMB'000

RMB'000

Liyi Chen

6,634

6,719

 

The amount is interest-free, unsecured and repayable on demand.

 

7. SHARE CAPITAL

Details of share capital are given in Note 24 to the consolidated financial statements.

 

8. EMPLOYEES, DIRECTORS' REMUNERATION AND SHARE-BASED PAYMENTS

 

Apart from the Directors, this Company has no employees. Details of the remuneration of Directors including share-based payments are shown in Note 28 to the consolidated financial statements, with further details regarding the share-based payments (all of which relate to this Company) in Note 24 to the consolidated financial statements.

 

Directors' remuneration of RMB388,000 (relating to Mr. Chong Cao and Mr. Nicholas James Lyth) has been borne by this Company.

 

 

 

9. AUDITORS' REMUNERATION

 

Details of the remuneration of auditors are given in Note 6 to the consolidated financial statements.

 

10. RELATED PARTY TRANSACTIONS

 

Apart from the information as disclosed in Notes 4, 5, 6 and 8 above, the Company had no other material transactions with its related parties during the year.

 

11. FINANCIAL RISK MANAGEMENT, OBJECTIVES AND POLICIES

 

The Company's activities expose it to a variety of financial risks: foreign exchange risk, credit risk, liquidity risk and cash flow interest rate risk. The Company's overall risk management programme seeks to minimise potential adverse effects on the Company's financial performance.

 

(a) Categories of financial instruments

2013

2012

Financial

Financial

liabilities

liabilities

measured at

measured at

Loans and

amortised

Loans and

amortised

receivables

cost

receivables

cost

RMB'000

RMB'000

RMB'000

RMB'000

Other receivable

-

-

77

-

Cash and cash equivalents

38

-

261

-

Accrued expenses and other

payables

-

536

-

543

Amount due to a subsidiary

-

2,172

-

803

Amount due to a shareholder

-

605

-

612

Amount due to a director

-

6,634

-

6,719

38

9,947

338

8,677

 

(b) Financial risk factors

 

Foreign exchange risk

 

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

 

As most of the transactions of the Company were settled in Sterling, the functional currency of the Company, it did not have significant exposure to foreign exchange risk.

 

During the year ended 31 December 2013, the Company had not entered into any forward exchange contracts.

 

 

 

11. FINANCIAL RISK MANAGEMENT, OBJECTIVES AND POLICIES (CONT'D)

 

(b) Financial risk factors (cont'd)

 

Credit risk

 

Credit risk is the risk that a party to a financial instrument will cause a financial loss for the Company by failing to discharge an obligation.

 

The Company's credit risk is primarily attributable to amount due from a subsidiary and cash and cash equivalents. The Company's cash and cash equivalents were held by major financial institutions located in the UK, which management believes are of high credit quality. Accordingly, the overall c redit risk is considered limited.

 

Carrying amounts of financial assets as at 31 December 2013, which represented the amounts of maximum exposure to credit risk, were as follows :-

 

2013

2012

RMB'000

RMB'000

Other receivable

-

77

Cash and cash equivalents

38

261

38

338

 

Liquidity risk

 

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligations associated with financial liabilities.

 

The Company monitors its liquidity risk and maintains a level of cash and cash equivalents deemed adequate by the management to finance the Company's operations and to mitigate the effects of fluctuations in its cash flows.

 

Maturities of the financial liabilities of the Company as at 31 December 2013 were as follows :-

 

2013

2012

RMB'000

RMB'000

Total amounts of contractual undiscounted obligations :-

Accrued expenses and other payables

536

543

Amount due to a subsidiary

2,172

803

Amount due to a shareholder

605

612

Amount due to a director

6,634

6,719

9,947

8,677

Due for payment :-

Within one year or on demand

9,947

8,677

 

 

 

 

 

 

11. FINANCIAL RISK MANAGEMENT, OBJECTIVES AND POLICIES (cont'd)

 

(b) Financial risk factors (cont'd)

 

Interest rate risk

 

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

 

The Company's income and operating cash flows are substantially independent of the changes in market interest rates and the Company has no significant interest-bearing assets. The Company's exposure to changes in interest rates is mainly attributable to its short-term borrowings. The Company has not used any interest rate swaps to hedge its exposure to interest rate risk.

 

(c) Capital management

 

The primary objective of the Company's capital management is to ensure that it maintains a strong credit rating and healthy capital ratios in order to support its business and to secure shareholders' investments.

 

The Company manages its capital structure and makes adjustments if required. To maintain or adjust the capital structure, the Company may return capital to shareholders by the means of share buy-backs or issue new shares. No changes were made in the objectives, policies or processes during 2013 and 2012.

 

As the Company operates in a high growth, fast moving industry, it is the Company's policy to maintain a high degree of flexibility in its capital structure by maintaining a high availability of liquid funds. The Company monitors its capital base using the equity ratio, which is total equity attributable to the company's equity holders divided by total assets. The Group's current policy is to maintain an equity ratio of 50% or higher.

 

2013

2012

RMB'000

RMB'000

Total assets

75,475

75,775

Total equity attributable to the Company's equity holders

65,528

67,098

Equity ratio

86.8%

88.5%

(d) Fair value estimation

 

(i) Financial instruments carried at fair value. At 31 December 2013, the Company did not have any financial instruments carried at fair value.

 

(ii) Fair value of financial instruments carried at other than fair value

 

The carrying amounts of the Company's financial instruments carried at cost or amortised cost were not materially different from their fair values as at 31 December 2013 and 2012.

 

At the balance sheet date, the carrying value of the investment in subsidiaries was above the market capitalisation of the group, but the directors do not consider this to be indicative of an impairment in this investment.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR SEAFLWFLSEIM

Related Shares:

TAIH.L
FTSE 100 Latest
Value8,809.74
Change53.53